PacificGMP makes two senior appointments

23 February 2016

UK-based life sciences firm Abzena (AIM: ABZA) says that its US biomanufacturing subsidiary PacificGMP has made two senior appointments to support its growth.

PacificGMP is a contract process development and manufacturing company based in San Diego, acquired by Abzena last year for $7.7 million (The Pharma Letter September 14, 2015).

Jon Strauss has been appointed director of manufacturing at PacificGMP. He joins from biotech giant Genentech, part of Roche, where, for the last five years, he was involved in all aspects of the manufacture of biopharmaceuticals. He was previously a senior scientist at CMC Biologics, having also worked at Momenta and Bayer Healthcare.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK